When it is available, will we take it? Public perception of hypothetical COVID-19 vaccine in Nigeria

INTRODUCTION

The novel coronavirus disease 2019 (COVID-19) caused by the Severe Acute Respiratory coronavirus 2 was first discovered in Wuhan Animal Market, Hubei Province, China in December 2019 [1]. Since its discovery, it has spread to more than 200 countries around the world and has been declared a pandemic by the World Health Organization [2]. COVID-19 has had unprecedented impacts on the health and well-being of people all over the world, as well as the economy of many countries [3, 4]. In Nigeria, the index case was reported on 27 February 2020, and more than 50,000 cases and over a thousand deaths have been documented since then [5].

As with past outbreaks, the novel nature of the current coronavirus outbreak implied that no definitive therapy existed for its treatment, instead, empirical therapies are being employed to manage the disease [1]. The rapid spread of the virus and continuous increasing number of cases alongside the partial and/or total lockdown protocols in most countries necessitate the urgent development of accurate diagnostic methods, effective treatments, and vaccines for the disease [6]. The long-term solution to COVID-19, however, would most likely be a safe, globally implemented vaccination program with a broad range of clinical and socioeconomic benefits [7]. It is of point to note that vaccination is one of the greatest achievements of modern medicine and it is the greatest human intervention besides clean water and sanitation [8].

Major infections such as smallpox and rinderpest have been eradicated worldwide due to vaccines, while polio has almost been eradicated with the exception of Afghanistan and Pakistan where it is still endemic [9,10,11]. The impact of vaccination on vaccine-preventable diseases cannot be overemphasized. The incidence and prevalence of diseases such as cervical cancer, hepatitis, yellow fever, tuberculosis, cholera, and tetanus, among others, have been severely reduced due to vaccine availability [12]. Vaccination plays such important roles in the fight against disease eradication and elimination, control of mortality, morbidity and complications, mitigation of disease severity, prevention of infection and even protection of unvaccinated population through herd immunity [8]. Thus, the availability of COVID-19 vaccine(s) will drastically change the course of the pandemic. As of 9 September 2020, 35 vaccine candidates are in clinical evaluation and 145 vaccine candidates are in preclinical evaluation [13].

Despite the immense benefits that vaccination has offered since the first discovery of the smallpox vaccine by Edward Jenner till date, saving millions of lives globally and doing so at a comparatively low cost, vaccine hesitancy has always plagued this great discovery. Vaccine hesitancy is “the reluctance or refusal to vaccinate despite the availability of vaccines” [14]. It was classified as one of the top ten threats to global health by the World Health Organization in 2019 [14]. Vaccine hesitancy is a complex phenomenon, with a growing continuum between vaccine acceptance and refusal. Despite the proven effectiveness and safety of vaccines, an increasing number of individuals perceive vaccines as unsafe and unnecessary [15]. In recent times, there has been a steady decline in vaccine coverage and an increase in the occurrence of vaccine-preventable diseases. For instance, there has been a 30% rise in measles cases globally. Vaccine hesitancy is believed to contribute greatly to this [14,15].

Nigeria is the most populated country in Africa and has a convoluted history of vaccine hesitancy. Vaccination coverage in Nigeria has continuously dropped since its peak of 81.5% in the 1990s, and by 2013, only 25% of children under the age of 2 were fully vaccinated [16] The 2003/2004 polio vaccine refusal in Nigeria had a far-reaching effect. It increased the incidence of polio by many folds in Nigeria and contributed to outbreaks of polio across three other continents [17]. Vaccine hesitancy could have a direct and wide-reaching effect on the acceptance of COVID-19 vaccine(s) by individuals in the community as it confers threat not only on the hesitant individual but on the community as a whole, as delays and refusals would make it impossible for communities to reach the threshold of vaccine uptake necessary for the conferment of herd immunity. While the focus of attention currently is on developing a vaccine to protect the population against COVID-19, stakeholders should prepare for the next challenge: vaccine adoption (access and acceptance) among the public. Our study aims to understand the perception of the public in Nigeria towards the hypothetical COVID-19 vaccine.

Methods

Results

Percentage distribution of respondents’ reservation toward vaccination, acceptance of COVID-19 vaccine and reasons for non-acceptance of COVID-19 vaccine

The results showed that 385 (74.6%) are willing to receive COVID-19 vaccine. 124 (24.0%) have reservations toward vaccination (Figure 1). The major reason for non-acceptance of the COVID-19 vaccine among our respondents is the unreliability of the clinical trials 49 (37.1%), followed by the belief that their immune system is enough to combat the virus 36 (27.3%) as shown in Figure 2.

• Download figure
• Open in new tab

Figure 1: Percentage distribution of respondents reservations toward vaccination and acceptance of COVID-19 vaccine [n=517]

Percentage distribution of respondent’s reservations toward vaccination and acceptance of the COVID-19 vaccine.

• Download figure
• Open in new tab

Figure 2: Reasons for non-acceptance of COVID-19 vaccine by our respondents [n=132]

Reasons for non-acceptance of the COVID-19 vaccine by our respondents.

DISCUSSION

This study is the first in Nigeria to assess the public perception towards the hypothetical COVID-19 vaccine. It has been documented that the public perception of vaccination governs the effectiveness of vaccination programs [20]. There is no specific antiviral treatment for COVID-19, and no vaccine is currently available [1]. Vaccination, one of the greatest advances in medicine, is one of the most effective tools for reducing the burden of infectious diseases. Over the last 20 years, worldwide, vaccination programs for polio, whooping cough, diphtheria, and measles have significantly reduced the prevalence of these diseases [9]. Despite the benefit vaccination reap for public health, this fundamental effort for disease control still faces major obstacles globally, and Nigeria is not an exception [21]. It has been noted that one of the major obstacles to vaccine acceptance is the public perception of the relative risks and benefits of vaccination [22].

Findings from our study revealed that there is no significant association between COVID-19 vaccine acceptance and sex. This contrasts with a multi-national survey in Europe, where there was a significant association between the two variables and a significantly higher proportion of males were willing to get vaccinated [23]. Even though there is no significant difference in the willingness to take the COVID-19 vaccine and sex, males are slightly willing to take the COVID-19 vaccine than females. Our results also revealed a significant association between age group and COVID-19 vaccine acceptance, with respondents age 16 to 30 more willing to take the COVID-19 vaccine. One might argue that the group who currently disagreed with taking the COVID-19 vaccine may be the most relevant. However, these sets of people can easily be persuaded to get vaccinated to achieve herd immunity; if they are informed of the benefits, vaccination can reap for public health.

Regarding the COVID-19 vaccine acceptance, about 74% of our respondents agreed to take the COVID-19 vaccine when it is available. This is higher than what was reported in South Africa (64%), Russia (54%), Poland (56%), Hungary (56%), and France (59%), according to a recent World Economic Forum’s Ipsos survey of nearly 20,000 adults on whether they will take COVID-19 vaccine or not when it is available [24]. However, the willingness to take the COVID-19 vaccine was higher in China (97%), Brazil (88%), Australia (88%), and India (87%) [24] compared to our study. A study in Indonesia also reported that for a 95% effective COVID-19 vaccine, 93.3% would take it [25]. Another study in Malaysia revealed that 94.3% of the respondents would take the COVID-19 vaccine [26].

Finding from our study also revealed that geographical location and acceptance of the COVID-19 vaccine are significantly associated. This is evident in that respondents from the Southern part of the country are likely to take the COVID-19 vaccine compared to the Northern part of the country. This is not surprising because previous studies have reported high levels of vaccine refusal in the northern part of Nigeria [27,28]. For instance, in 2003, five northern Nigerian states boycotted the oral polio vaccine due to fears that it was unsafe [17]. However, these findings don’t necessarily imply that refusal would be higher in Northern Nigeria; it thus strengthens the need to reassure the public of the safety of the COVID-19 vaccine irrespective of their geographical location. The acceptance level of the COVID-19 vaccine, according to our study, is lower than that of the hypothetical Ebola vaccine (80%) [29] and malaria vaccine (96%) [30] in previous studies conducted in Nigeria.

Furthermore, about 25% of our respondents disagreed with taking the COVID-19 vaccine when it is available. This is higher than what was reported in China (3%), Brazil (12%), Australia (12%), India (13%), Malaysia (15%), Great Britain (15%), Saudi Arabia (16%), South Korea (16%), Peru (21%), and Canada (24%) according to a recent World Economic Forum’s Ipsos survey of nearly 20,000 adults on whether they will take COVID-19 vaccine or not when it is available [24]. However, the unwillingness to take the COVID-19 vaccine was higher in Russia (47%), Poland (45%), Hungary (44%), France (41%), South Africa (36%), Sweden (33%), United States (33%), Germany (33%) and Italy (33%) [24] compared to our study.

Findings from our study also revealed that the top three reasons for non-acceptance of the COVID-19 vaccine are the unreliability of clinical trials, the immune system is enough to combat COVID-19, and that the COVID-19 vaccine is not safe. This is similar to what was reported by the Ipsos survey, where the top 3 reasons were “worry about side effects”, “doubt about the vaccine effectiveness”, and “perception of not being enough at risk from COVID-19” [24]. Another multi-national study in Europe revealed that more than half said they were concerned about the potential side effects of the vaccine [23]. This is not surprising in that all these findings have been found in literature as some of the reasons for vaccine hesitancy [31,32]. It has also been documented in the literature that vaccine adoption is a sum of vaccine access and acceptance [33]. Interestingly, one of the reasons for the non-acceptance of the COVID-19 vaccine is the vaccine’s perceived high cost according to our findings.

Findings from this study revealed 25% of our respondent will not accept the COVID-19 vaccine. Thus, there is a possible implication of influencing others with their perception of the COVID-19 vaccine leading to more people refusing the vaccine. This could lead to widespread refusal of COVID-19 vaccine due to eroded public trust with the negative information regarding the COVID-19 vaccine. The estimated reproductive number of COVID-19 for Nigeria has been determined to be 2.63 [34]. Going by the formula Q = 1 – 1/R, where Q is the herd immunity threshold and R is the reproductive number [35], an estimated 62% or more of the Nigerian population must be vaccinated to achieve herd immunity. For Nigeria to achieve this, national health authorities need to devise means to ensure the public trust is earned and all communities, including the marginalized populations, must be engaged properly to ensure an increase in vaccine acceptance. In addition, all information regarding the vaccine must be made public, quality control and assurance must also be the priority of the health authorities.

Access is also an important factor to be considered as regards the COVID-19 vaccine, and it is essential to translate the willingness to be vaccinated into actual vaccination decisions when the vaccine becomes available. Even though our study did not assess the willingness to pay for the COVID-19 vaccine, equitable access to vaccination is much-needed to quickly achieve herd immunity.

LIMITATIONS

Our study is not without its limitations. Generalization of the survey results should be avoided because the pattern of questionnaire distribution may influence the outcome. We used the social media platform, so it may omit older adults, people from lower socioeconomic classes, certain geographical locations, lower educational attainment, and those who were illiterates as well as people who did not have access to the internet. Besides, response/social bias is also a possibility which is not uncommon in self-administered questionnaire research. Finally, acceptance was assessed using a potential (hypothetical) vaccine, which may differ from the respondents’ revealed preferences when the vaccine becomes available. Thus, future study may need to put all these gaps into consideration to ensure a far-reaching conclusion in this regard.

CONCLUSION

Even though most of our respondents are willing to take the COVID-19 vaccine, our findings reiterate the need to reassure the public that any vaccine which becomes available will be safe and effective. Otherwise, there is a risk of a reversal of hard-won achievement of building public trust in Nigeria’s vaccination programme, potentially compromising reaching community immunity. Public trust is important in promoting public health and plays an essential role in the public’s compliance with vaccination programs and other health interventions. However, if the public trust is eroded, false information can spread, leading to the rejection of health interventions with a major threat to public health. Besides, national health authorities, stakeholders and policymakers in Nigeria need to ensure that access to the COVID-19 vaccine is equitable when it becomes available.

Funding

We have not received any financial support for this manuscript.

Authors contribution

Yusuff Adebayo Adebisi and Aishat Jumoke Alaran conceptualized the study. Yusuff Adebayo Adebisi, Obasanjo Afolabi Bolarinwa and Aishat Jumoke Alaran wrote the first draft of the paper and performed data analysis. Wuraola Akande-Sholabi and Don Eliseo Lucero-Prisno III critically reviewed and suggested important improvements to the manuscript. All authors read and approved the final manuscrip.

Ethics Approval

Ethical approval was not necessary because the study focussed on perception of our respondents and no confidential information was asked.

Consent for publication

Not applicable

Conflicts of interest

The authors declared no conflicts of interest.